Research interest centers on the compound's proposed capacity to potentiate HGF activity at the MET receptor, with particular attention to downstream effects on synaptic density and cognitive function-related signalling in neurological research models
Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
In addition, we induced in vivo experimental hypoprolactinemia, treating mice with bromocriptine, a dopamine receptor agonist that inhibits pituitary PRL secretion
Cagrilintide is the single amylin-analog molecule
It goes straight into the blood, avoiding the stomach
It grows well at low to mid-elevations in the forests of tropical and subtropical regions
